Alison E Simmons
Overview
Explore the profile of Alison E Simmons including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
71
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ximenes R, Simmons A, Gebretekle G, Nam A, Wong E, Salvadori M, et al.
Vaccine
. 2025 Mar;
54:126985.
PMID: 40054141
Background: A 21-valent pneumococcal conjugate vaccine (PCV21) was recently authorized in Canada to protect adults against invasive pneumococcal disease (IPD). Objective: To assess the cost-effectiveness of PCV21 compared to current...
2.
Rudd M, Simmons A, Gebretekle G, Tuite A
Can Commun Dis Rep
. 2025 Feb;
51(2-3):54-67.
PMID: 39991551
Background: Two respiratory syncytial virus (RSV) vaccines are currently approved for use in adults aged 60 years and older in Canada. Objective: To conduct a multi-model comparison to explore the...
3.
Simmons A, Gebretekle G, Pless R, Wierzbowski A, Tunis M, Tuite A
Can Commun Dis Rep
. 2025 Feb;
51(2-3):68-83.
PMID: 39980573
Background: Two pneumococcal conjugate vaccines, covering 15 and 20 serotypes (Pneu-C-15 and Pneu-C-20, respectively), were recently approved for use in the Canadian paediatric population. Objective: To assess the cost-effectiveness of...
4.
Simmons A, Ximenes R, Gebretekle G, Salvadori M, Wong E, Tuite A
Can Commun Dis Rep
. 2025 Feb;
51(2-3):84-91.
PMID: 39980572
Background: In July 2024, Health Canada authorized a 21-valent pneumococcal conjugate vaccine (Pneu-C-21) for use in adults. Objective: To conduct a systematic review of the cost-effectiveness of Pneu-C-21 for preventing...
5.
Tuite A, Simmons A, Rudd M, Cernat A, Gebretekle G, Yeung M, et al.
CMAJ
. 2024 Sep;
196(29):E989-E1005.
PMID: 39251240
Background: Respiratory syncytial virus (RSV) vaccines could reduce disease burden and costs in older Canadian adults, but vaccination program cost-effectiveness is unknown. We evaluated the cost-effectiveness of different age cut-offs...
6.
Gebretekle G, Yeung M, Ximenes R, Cernat A, Simmons A, Killikelly A, et al.
Vaccine
. 2024 Jul;
42(21):126164.
PMID: 39079810
Background: Health Canada recently authorized the RSVpreF pregnancy vaccine and nirsevimab to protect infants against respiratory syncytial virus (RSV) disease. Objective: Assess the cost-effectiveness of RSVpreF and nirsevimab programs in...
7.
Fisman D, Simmons A, Tuite A
Vaccine
. 2024 Jul;
42(25):126134.
PMID: 39004528
Though widely applied in other epidemiological fields, the case-cohort study design has seen little application in the field of vaccinology. Case-cohort studies use probabilistic sampling and reweighting to draw inferences...
8.
Peng A, Bosco S, Simmons A, Tuite A, Fisman D
PNAS Nexus
. 2024 Mar;
3(2):pgae065.
PMID: 38463611
Mask use for prevention of respiratory infectious disease transmission is not new but has proven controversial during the SARS-CoV-2 pandemic. In Ontario, Canada, irregular regional introduction of community mask mandates...
9.
Awan A, Shakik S, Banack H, Fisman D, Simmons A
PLoS One
. 2023 Apr;
18(4):e0284323.
PMID: 37058469
Background: A better understanding of links between mental illness and risk of bloodborne infectious disease could inform preventive and therapeutic strategies in individuals with mental illness. Methods: We performed a...
10.
Simmons A, Amoako A, Grima A, Murison K, Buchan S, Fisman D, et al.
PLoS One
. 2023 Mar;
18(3):e0283715.
PMID: 37000810
Background: Vaccines against SARS-CoV-2 have been shown to reduce risk of infection as well as severe disease among those with breakthrough infection in adults. The latter effect is particularly important...